Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:29 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 500 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus ( Type 1 and Type 2) Clear all
Not yet recruiting Phase 2 Interventional

Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.

NCT07325201
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis, Ketones
Interventions
Sotagliflozin initiation
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Terminated Phase 4 Interventional

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

NCT00961207
View directory record Official record
Conditions
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria, Albuminuria
Interventions
Aliskiren
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Nov 1, 2026, 2:29 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

NCT02120976
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
JTT-252 or Placebo, JTT-252
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Nov 1, 2026, 2:29 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Culinary Medicine vs. Nutrition Education in Diabetes

NCT05019274
View directory record Official record
Conditions
Primary Disease: 1. Type 2 Diabetes
Interventions
Culinary Medicine Intervention, Standard of Care Nutrition Visits
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting Phase 4 Interventional

A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers

NCT07159282
View directory record Official record
Conditions
Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer Due to Type 1 Diabetes Mellitus, Diabetic Foot Ulcer
Interventions
XWRAP
Other
Lead sponsor
Applied Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Terminated Phase 4 Interventional Results available

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

NCT04567225
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Nov 1, 2026, 2:29 AM EST
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide

NCT06422325
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC closed-loop system in insulin only mode, MPC closed-loop system in insulin/pramlintide mode
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Completed Phase 1 Interventional

TAK-875 Glimepiride Drug-Interaction Study

NCT01496443
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TAK-875 and Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Nov 1, 2026, 2:29 AM EST
Terminated Phase 1 Interventional Results available

A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

NCT05510245
View directory record Official record
Conditions
Type 2 Diabetes, Renal Impairment
Interventions
PF-07081532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Nov 1, 2026, 2:29 AM EST
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop Study MPC vs FMPD

NCT04771403
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
FMPD AP algorithm, MPC AP system, Dexcom G6 Continuous Glucose Monitoring (CGM) System
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Nov 1, 2026, 2:29 AM EST
Not yet recruiting Not applicable Interventional

Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction

NCT07165327
View directory record Official record
Conditions
Gestatiaonl Diabetes Mellitus, Pregnancy, Diabetes in Pregnancy, Insulin Dependent Diabetes Mellitus, Insulin
Interventions
Injection Port for Insulin Administration, Single-Use Insulin Needles
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Nov 1, 2026, 2:29 AM EST
Completed Phase 1Phase 2 Interventional

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

NCT04305054
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab, Lenvatinib, Favezelimab/Pembrolizumab, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Terminated Phase 3 Interventional

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

NCT00449605
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Glimepiride, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Nov 1, 2026, 2:29 AM EST
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop Study R-AP vs MPC

NCT05083559
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC AP algorithm, Robust R-AP algorithm
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting Not applicable Interventional

ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

NCT05463289
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes, Cystic Fibrosis-related Diabetes
Interventions
Point of Care Autonomous AI diabetic retinopathy exam
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 21 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Completed Not applicable Interventional Results available

Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose

NCT00741390
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
BD/33G, OTM / 33G, OTU/28G, ACC/28G, OTM/28G
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Colorado Springs, Colorado • Carlstadt, New Jersey • Paramus, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting Not applicable Interventional

Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes

NCT07864168
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Next Generation Extended Wear Sensors
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Chula Vista, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting Phase 1Phase 2 Interventional

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574
View directory record Official record
Conditions
Type 1 Diabetes, New Onset
Interventions
Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
9 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Completed Not applicable Interventional

Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children

NCT06604871
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin Pump with Continuous Glucose Monitoring
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 6 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Nov 1, 2026, 2:29 AM EST
Completed No phase listed Observational

A 2-Month Safety Follow-Up Trial

NCT00741429
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Technosphere Insulin Inhalation Powder, Comparator
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
109
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Nov 1, 2026, 2:29 AM EST
Completed Not applicable Interventional Results available

Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices

NCT04020822
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Guardian Sensor (3)
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Nov 1, 2026, 2:29 AM EST
Completed Phase 2 Interventional Results available

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

NCT00662857
View directory record Official record
Conditions
Diabetes Mellitus: Type 1
Interventions
Technosphere Insulin® Inhalation Powder, RAA Population
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Nov 1, 2026, 2:29 AM EST
Completed Not applicable Interventional

Extension for Community Health Outcomes (ECHO) Diabetes Program

NCT06552923
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
ECHO Tele-Education
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
32,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Davis, California • Fresno, California • Multiple Locations, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Nov 1, 2026, 2:29 AM EST
Completed Phase 2 Interventional

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

NCT06152042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
North Miami Beach, Florida • Morehead City, North Carolina • Norman, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 1, 2026, 2:29 AM EST